» Articles » PMID: 21236489

Effects of Exogenous Agmatine in Human Leukemia HMC-1 and HL-60 Cells on Proliferation, Polyamine Metabolism and Cell Cycle

Overview
Journal Leuk Res
Date 2011 Jan 18
PMID 21236489
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Impairment of agmatine homeostasis is involved in the regulation of cell proliferation in malignant solid tumors. The present study aimed at analyzing the relevance of agmatine homeostasis in pathophysiology of human leukemia. Proliferation of the human leukemia cells HMC-1 and HL-60 was determined in the absence or presence of agmatine. Apoptosis and cell cycle distribution was investigated by determination of caspase-3 activity and/or flow cytometry after staining with propidium iodide. Expression analysis was performed by qPCR and by a microarray genechip. Exogenous agmatine inhibited proliferation of both HMC-1 and HL-60 cells. The antiproliferative effect was due to interference of agmatine with the cell cycle with no evident signs of apoptosis. Comparative analysis of expression of mRNA in untreated HMC-1 cells and in non-leukemic human mast cells revealed a much lower expression of agmatinase and diamine oxidase in HMC-1 cells indicating a significantly reduced agmatine catabolism in the leukemic cells. At the mRNA level, inhibition of proliferation of both cell lines by agmatine was associated with cell type-specific alterations of the expression of enzymes of the polyamine pathway. The present results point to a significant role of agmatine homeostasis in the (patho)physiology of cell proliferation of leukemic cells, at least in HMC-1 and HL-60 cells, that may serve as a potential target for an adjuvant therapy in the treatment of human leukemia.

Citing Articles

Agmatinase facilitates the tumorigenesis of pancreatic adenocarcinoma through the TGFβ/Smad pathway.

Zhang Y, Cao L, Xie Y, Wang C, Liu X, Zhang X Exp Ther Med. 2022; 24(2):490.

PMID: 35837051 PMC: 9257765. DOI: 10.3892/etm.2022.11417.


Arginine depriving enzymes: applications as emerging therapeutics in cancer treatment.

Kumari N, Bansal S Cancer Chemother Pharmacol. 2021; 88(4):565-594.

PMID: 34309734 DOI: 10.1007/s00280-021-04335-w.


Agmatinase promotes the lung adenocarcinoma tumorigenesis by activating the NO-MAPKs-PI3K/Akt pathway.

Zhu H, Yin J, Chen D, He S, Chen H Cell Death Dis. 2019; 10(11):854.

PMID: 31699997 PMC: 6838094. DOI: 10.1038/s41419-019-2082-3.


Safety and neurochemical profiles of acute and sub-chronic oral treatment with agmatine sulfate.

Bergin D, Jing Y, Williams G, Mockett B, Zhang H, Abraham W Sci Rep. 2019; 9(1):12669.

PMID: 31481723 PMC: 6722093. DOI: 10.1038/s41598-019-49078-0.


Recent advances in our understanding of mast cell activation - or should it be mast cell mediator disorders?.

Theoharides T, Tsilioni I, Ren H Expert Rev Clin Immunol. 2019; 15(6):639-656.

PMID: 30884251 PMC: 7003574. DOI: 10.1080/1744666X.2019.1596800.